ArticleThoracic cancer2026
Revisiting Thoracic Duct Resection in Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis and Immunologic Insight Into Recurrence Risk.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis. In an effort to reduce recurrence, the thoracic duct (TD), a key conduit for immune and nutritional homeostasis, is sometimes resected during esophagectomy. The clinical and immunological impact of this procedure remains controversial. This study therefore aimed to evaluate the prognostic significance of intraoperative thoracic duct resection (TDR) in ESCC patients.
methodsWe retrospectively analyzed 722 patients with ESCC who underwent McKeown esophagectomy at Sun Yat-sen University Cancer Center between January 2020 and December 2022. Patients were classified into TDR and TD-preserved groups. Propensity score matching (PSM) was used to balance baseline characteristics. Overall survival (OS) and recurrence-free survival (RFS) were compared using Kaplan-Meier analysis and Cox regression models.
resultsAfter PSM, there were no significant differences between the TDR and TD-preserved groups in median OS (both 33.96 months) or in 1-, 3-, and 5-year OS rates (p = 0.66). RFS was also similar (p = 0.31). Subgroup analyses showed that TDR had no significant impact on OS or RFS, regardless of adjuvant therapy or immunotherapy at recurrence. However, among patients without lymph node metastasis (pN0), TDR was associated with a higher recurrence risk (HR, 2.09; 95% CI, 1.16-3.73; p = 0.013).
conclusionsIntraoperative TDR did not improve long-term survival in ESCC and may increase recurrence risk in early-stage node-negative patients. Routine TDR should be avoided, and its indication individualized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.